Ovarian cancer is the most common cause of death among patients with malignant tumors of the reproductive system. The lack of the serous ovarian membrane leads to the rapid penetration of tumor cells into the free abdominal cavity and to the distribution with peritoneal fluid flow through the anatomical pockets of the peritoneum. In recent years, much attention has been paid to the possibilities of local intraperitoneal chemotherapy. Intraperitoneal therapy at supranormal temperature can reduce the severity of intraperitoneal chemotherapy complications and increase the effectiveness of the procedure. This technique is called hyperthermic intraperitoneal chemotherapy (HIPEC). The latter plays an important role in predicting the survival of patients with recurrent initially advanced ovarian cancer, along with the degree of spread of the process and the possibility of complete cytoreduction. The paper gives the Russian and foreign data on the efficiency of HIPEC, which are present in the literature over the past 10 years, as well as the pathophysiological substantiation for positive treatment results after this therapy option. It describes the main clinical protocols using HIPEC and shows its role in the treatment of primary and recurrent ovarian cancer.